|
Dec 1
|
The Zacks Analyst Blog Highlights Avidity, Bristol Myers Squibb, Vertex, Arcturus and BioVie
|
|
Dec 1
|
Bristol Myers Stock Is Slumping. One Director Bought Up Shares.
|
|
Nov 30
|
Biotech Stock Roundup: RNA Up on BMY Deal Expansion, BIVI Down on Setback & More
|
|
Nov 30
|
Insiders At Bristol-Myers Squibb Sold US$23m In Stock, Alluding To Potential Weakness
|
|
Nov 30
|
13 Best Stocks Under $50 To Buy Now
|
|
Nov 29
|
Avidity (RNA) Expands Collaboration With BMY, Shares Rise
|
|
Nov 29
|
CAR T-Cell Therapies Under FDA Watch on Reports of Malignancies
|
|
Nov 28
|
FDA Looking Into All Approved CAR T Therapies on Risk of Cancer in White Blood Cells
|
|
Nov 28
|
Avidity Stock Soars on Collaboration Deal With Bristol Myers
|
|
Nov 28
|
Bristol Myers pours $100M into RNA drugs for cardiovascular diseases
|
|
Nov 28
|
Avidity Biosciences Announces Expansion of Cardiovascular Collaboration with Bristol Myers Squibb for up to Five Targets Utilizing Avidity's Proprietary AOC™ Platform Technology
|
|
Nov 26
|
3 Resilient Stocks with Massive Potential to Boost Your Wealth
|
|
Nov 26
|
15 Best Drug Stocks To Invest In
|
|
Nov 26
|
Bristol-Myers Squibb Company (NYSE:BMY) Delivered A Better ROE Than Its Industry
|
|
Oct 12
|
With 78% institutional ownership, Bristol-Myers Squibb Company (NYSE:BMY) is a favorite amongst the big guns
|
|
Oct 12
|
Biotech Stock Roundup: BMY Grabs MRTX, AKRO Down on Study Data, ALNY Faces Setback
|
|
Oct 12
|
Bristol Myers Squibb to Showcase Data Demonstrating Improved Outcomes in Earlier Stages of Cancer, Durable Long-Term Benefits with Opdivo-Based Regimens, and Addressing High Unmet Needs in Multiple Tumor Types at ESMO 2023
|
|
Oct 11
|
Sotyktu (deucravacitinib) Long-Term Data Demonstrate Durable Efficacy and Consistent Safety for up to Three Years in Moderate-to-Severe Plaque Psoriasis
|
|
Oct 11
|
The Zacks Analyst Blog Highlights Bristol Myers Squibb, Mirati Therapeutics, Eli Lilly, POINT Biopharma and Pfizer
|
|
Oct 11
|
Bristol Myers Squibb Presents New Zeposia (ozanimod) Data on Long-Term Disease Progression and Cognition in Patients with Relapsing Forms of Multiple Sclerosis
|